TRex Bio
South San Francisco
About TRex Bio
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $169.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2024)
- Website: trex.bio
Industries & Categories
Bioinformatics, Biopharma, Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/trex-bio-87255 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.